These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27720936)

  • 21. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
    Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
    J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma.
    Gibouin VC; Durand M; Boudesco C; Hermetet F; Nozickova K; Chassagne-Clement C; Abdelwahed M; Klener P; Garrido C; Jego G
    Leukemia; 2024 Aug; 38(8):1742-1750. PubMed ID: 38906964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
    Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin.
    Rink JS; Yang S; Cen O; Taxter T; McMahon KM; Misener S; Behdad A; Longnecker R; Gordon LI; Thaxton CS
    Mol Pharm; 2017 Nov; 14(11):4042-4051. PubMed ID: 28933554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
    Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia.
    Wakim J; Arman E; Becker-Herman S; Kramer MP; Bakos E; Shachar I; Elson A
    Oncogene; 2017 Jun; 36(26):3686-3694. PubMed ID: 28166196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
    Dunleavy K; Erdmann T; Lenz G
    Cancer Treat Rev; 2018 Apr; 65():41-46. PubMed ID: 29549872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
    Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
    Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
    J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.
    Liu QH; Dai GR; Wang XN; Wang L; Li LL; Wu ZS; Xia RX
    Cancer Gene Ther; 2022 Aug; 29(8-9):1207-1216. PubMed ID: 35082399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.
    Yamagishi M; Katano H; Hishima T; Shimoyama T; Ota Y; Nakano K; Ishida T; Okada S; Watanabe T
    Sci Rep; 2015 Dec; 5():17868. PubMed ID: 26639163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
    Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.
    Chen JL; Chu PY; Huang CT; Huang TT; Wang WL; Lee YH; Chang YY; Dai MS; Shiau CW; Liu CY
    Mol Med; 2022 Aug; 28(1):93. PubMed ID: 35941532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma.
    Huang X; Shen Y; Liu M; Bi C; Jiang C; Iqbal J; McKeithan TW; Chan WC; Ding SJ; Fu K
    Am J Pathol; 2012 Jul; 181(1):26-33. PubMed ID: 22609116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 40. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma.
    Meriranta L; Sorri S; Huse K; Liu X; Spasevska I; Zafar S; Chowdhury I; Dufva O; Sahlberg E; Tandarić L; Karjalainen-Lindsberg ML; Hyytiäinen M; Varjosalo M; Myklebust JH; Leppä S
    Blood Cancer Discov; 2024 Sep; 5(5):331-352. PubMed ID: 38630892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.